Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 2
2006 2
2009 1
2012 1
2013 2
2014 2
2015 2
2016 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Results by year

Filters applied: . Clear all
Page 1
Synthesis and characterization of 1,2,3,4,5-pentafluoroferrocene.
Sünkel K, Weigand S, Hoffmann A, Blomeyer S, Reuter CG, Vishnevskiy YV, Mitzel NW. Sünkel K, et al. Among authors: weigand s. J Am Chem Soc. 2015 Jan 14;137(1):126-9. doi: 10.1021/ja511588p. Epub 2014 Dec 26. J Am Chem Soc. 2015. PMID: 25531826
Characterization of Breast Cancer Preclinical Models Reveals a Specific Pattern of Macrophage Polarization.
Vallerand D, Massonnet G, Kébir F, Gentien D, Maciorowski Z, De la Grange P, Sigal-Zafrani B, Richardson M, Humbert S, Thuleau A, Assayag F, de Plater L, Nicolas A, Scholl S, Marangoni E, Weigand S, Roman-Roman S, Savina A, Decaudin D. Vallerand D, et al. Among authors: weigand s. PLoS One. 2016 Jul 7;11(7):e0157670. doi: 10.1371/journal.pone.0157670. eCollection 2016. PLoS One. 2016. PMID: 27388901 Free PMC article.
CD44 Isoform Status Predicts Response to Treatment with Anti-CD44 Antibody in Cancer Patients.
Birzele F, Voss E, Nopora A, Honold K, Heil F, Lohmann S, Verheul H, Le Tourneau C, Delord JP, van Herpen C, Mahalingam D, Coveler AL, Meresse V, Weigand S, Runza V, Cannarile M. Birzele F, et al. Among authors: weigand s. Clin Cancer Res. 2015 Jun 15;21(12):2753-62. doi: 10.1158/1078-0432.CCR-14-2141. Epub 2015 Mar 11. Clin Cancer Res. 2015. PMID: 25762343
First-in-human phase I clinical trial of RG7356, an anti-CD44 humanized antibody, in patients with advanced, CD44-expressing solid tumors.
Menke-van der Houven van Oordt CW, Gomez-Roca C, van Herpen C, Coveler AL, Mahalingam D, Verheul HM, van der Graaf WT, Christen R, Rüttinger D, Weigand S, Cannarile MA, Heil F, Brewster M, Walz AC, Nayak TK, Guarin E, Meresse V, Le Tourneau C. Menke-van der Houven van Oordt CW, et al. Among authors: weigand s. Oncotarget. 2016 Nov 29;7(48):80046-80058. doi: 10.18632/oncotarget.11098. Oncotarget. 2016. PMID: 27507056 Free PMC article. Clinical Trial.
13 results